Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma
| Autor: | Keita Iwasaki, Tanja Pejovic, Mian M.K. Shahzad, Yutaka Ueda, Lynda D. Roman, Takuhei Yokoyama, Sosuke Adachi, Shinya Satoh, Joseph L. Kelley, Hiroko Machida, Satoshi Takeuchi, Tadayoshi Nagano, Frederick R. Ueland, Stephen H. Bush, Dwight D. Im, Mayu Yunokawa, Shiori Yanai, Malcolm S. Ross, Erin A. Blake, Marian S. Johnson, Koji Matsuo, Tadao Takano, Takahito Miyake, Merieme Klobocista, Kosei Hasegawa, Masako Shida, Kohei Omatsu, Tsukasa Baba, Yuji Ikeda, Masato Nishimura, Munetaka Takekuma |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Bridged-Ring Compounds
Oncology medicine.medical_specialty Organoplatinum Compounds medicine.medical_treatment Salvage therapy Article Cohort Studies 03 medical and health sciences 0302 clinical medicine Carcinosarcoma Japan Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Retrospective Studies Salvage Therapy Univariate analysis Chemotherapy 030219 obstetrics & reproductive medicine Taxane business.industry Obstetrics and Gynecology Retrospective cohort study Middle Aged Chemotherapy regimen United States Regimen 030220 oncology & carcinogenesis Uterine Neoplasms Cohort Female Taxoids Neoplasm Recurrence Local business |
| Zdroj: | Gynecol Oncol |
| ISSN: | 0090-8258 |
| Popis: | OBJECTIVE: To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. METHODS: We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. RESULTS: There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P < 0.001). On multivariate analysis, use of taxane/platinum regimen was independently associated with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.35 to 0.91, P = 0.02). When stratified by disease-free interval, women with a disease-free interval ≥6 months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect